White Lighthouse Investment Management Inc. Acquires New Holdings in Intuitive Surgical, Inc. $ISRG

White Lighthouse Investment Management Inc. acquired a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 2,015 shares of the medical equipment provider’s stock, valued at approximately $819,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Plato Investment Management Ltd acquired a new position in shares of Intuitive Surgical during the second quarter valued at approximately $4,315,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Intuitive Surgical in the second quarter worth approximately $14,316,000. Hikari Power Ltd bought a new position in Intuitive Surgical during the 2nd quarter valued at $5,619,000. Nykredit A S bought a new position in Intuitive Surgical during the 2nd quarter valued at $48,464,000. Finally, NewEdge Advisors LLC increased its position in shares of Intuitive Surgical by 19.1% during the 2nd quarter. NewEdge Advisors LLC now owns 50,825 shares of the medical equipment provider’s stock valued at $20,212,000 after purchasing an additional 8,142 shares during the period. 83.64% of the stock is owned by institutional investors.

Key Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Q3 revenue increased 21.7% year over year to $3.05 billion, surpassing the $2.91 billion consensus estimate, while adjusted earnings of $3.00 per share exceeded expectations of approximately $2.65. Intuitive Surgical Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Underlying demand remained healthy: worldwide procedures grew approximately 15%, including about 14% growth in da Vinci procedures and 31% growth in Ion procedures. System placements also rose to 546 from 427 a year earlier. Intuitive Announces Third Quarter Earnings
• Positive Sentiment: Several analysts maintained bullish views or raised targets following the report, including JPMorgan, which lifted its target to $475 and kept an Overweight rating, while Bank of America reiterated Buy with a $470 target. Intuitive Surgical Buy Rating Reaffirmed

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG opened at $428.12 on Thursday. The stock has a market capitalization of $151.25 billion, a price-to-earnings ratio of 51.77, a PEG ratio of 3.30 and a beta of 1.46. Intuitive Surgical, Inc. has a 1-year low of $328.57 and a 1-year high of $603.88. The company has a 50 day moving average price of $393.50 and a 200 day moving average price of $408.89.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.35. Intuitive Surgical had a return on equity of 17.70% and a net margin of 25.54%. The company had revenue of $3.05 billion for the quarter, compared to analysts’ expectations of $2.91 billion. During the same quarter in the prior year, the company earned $2.40 earnings per share. The firm’s revenue was up 21.7% on a year-over-year basis. On average, sell-side analysts expect that Intuitive Surgical, Inc. will post 8.87 EPS for the current fiscal year.

Analyst Ratings Changes

ISRG has been the topic of a number of research reports. Erste Group Bank raised Intuitive Surgical from a “hold” rating to a “buy” rating in a research note on Wednesday. HSBC cut Intuitive Surgical from a “buy” rating to a “hold” rating and set a $391.00 target price for the company. in a research note on Thursday, July 30th. Evercore set a $430.00 target price on Intuitive Surgical in a research note on Monday, July 6th. Barclays reaffirmed an “overweight” rating and set a $500.00 target price (up from $485.00) on shares of Intuitive Surgical in a report on Wednesday. Finally, Piper Sandler reiterated an “overweight” rating on shares of Intuitive Surgical in a research report on Friday, August 21st. Twenty-five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus target price of $500.13.

Insider Buying and Selling at Intuitive Surgical

In related news, EVP Mark Brosius sold 77 shares of Intuitive Surgical stock in a transaction on Friday, August 21st. The stock was sold at an average price of $375.57, for a total value of $28,918.89. Following the transaction, the executive vice president directly owned 881 shares in the company, valued at $330,877.17. The trade was a 8.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gary Guthart sold 10,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $400.00, for a total value of $4,000,000.00. Following the sale, the director directly owned 1,245,679 shares in the company, valued at $498,271,600. This trade represents a 0.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 12,370 shares of company stock worth $4,891,989. 0.60% of the stock is owned by insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.